Get the Stockscreener App
42.06
0.00%
0.010
Merus N V stock is traded at $42.06, with a volume of 75,630.
It is up +0.00% in the last 24 hours and down -6.18% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$42.07
Open:
$41.77
24h Volume:
75,630
Relative Volume:
0.15
Market Cap:
$2.89B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-11.19
EPS:
-3.76
Net Cash Flow:
$-157.31M
1W Performance:
-0.90%
1M Performance:
-6.18%
6M Performance:
-28.90%
1Y Performance:
+52.98%
1-Day Range:
$41.40
$42.38
1-Week Range:
$41.40
$43.51
52-Week Range:
$27.11
$61.61
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
42.15 | 2.89B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.92 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.23 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.56 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.28 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.50 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Analysts Set Merus (NASDAQ:MRUS) Target Price at $85.64 - MarketBeat
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
4,122 Shares in Merus (NASDAQ:MRUS) Bought by MML Investors Services LLC - Defense World
Trend Tracker for (MRUS) - Stock Traders Daily
State Street Corp Sells 9,809 Shares of Merus (NASDAQ:MRUS) - Defense World
Swelling losses haven't held back gains for Merus (NASDAQ:MRUS) shareholders since they're up 201% over 5 years - Simply Wall St
HighTower Advisors LLC Purchases Shares of 7,231 Merus (NASDAQ:MRUS) - Defense World
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
US FDA approves Merus' therapy to treat lung, pancreatic cancers - MSN
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewswire
Merus Launches Phase 2 Trial for Novel Cancer Drug Petosemtamab in Advanced Colorectal Cancer - StockTitan
Merus N.V.'s SWOT analysis: antibody innovator's stock faces pivotal year - Investing.com
Franklin Resources Inc. Acquires 150,341 Shares of Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Technical Data - Stock Traders Daily
Lord Abbett & CO. LLC Purchases 328,316 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Janus Henderson Group PLC Has $944,000 Stake in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) versus Can-Fite BioPharma (NYSE:CANF) Critical Survey - Defense World
Merus (NASDAQ:MRUS) Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight - Insider Monkey
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy - Insider Monkey
Merus (NASDAQ:MRUS) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Wellington Management Group LLP Grows Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus’ (MRUS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Citi raises Merus target to $97 on positive trial data By Investing.com - Investing.com South Africa
Citi raises Merus target to $97 on positive trial data - Investing.com
Needham & Company LLC Reaffirms "Buy" Rating for Merus (NASDAQ:MRUS) - MarketBeat
The Manufacturers Life Insurance Company Has $2.56 Million Stock Position in Merus (NASDAQ:MRUS) - Defense World
Positive early data on Merus’ petosemtamab - The Pharma Letter
The Manufacturers Life Insurance Company Sells 11,463 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC - GlobeNewswire Inc.
Zwischenergebnisse der Monotherapie mit Petosemtamab von - GlobeNewswire
Merus's Cancer Drug Shows 36% Response Rate in Head & Neck Cancer Trial, Including Complete Responses - StockTitan
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - The Manila Times
Merus’ Petosemtamab Monotherapy Interim Data Continues to - GlobeNewswire
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - Business Upturn
FY2025 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus Scores Its First FDA Approval For Lung Cancer Drug - Benzinga
First for Merus, first for NRG1+ cancers: US FDA approves Bizengri - BioWorld Online
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers - Yahoo Finance
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' - Benzinga
A first for Merus’ Bizengri with FDA nod - The Pharma Letter
Guggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS) - Defense World
William Blair Has Bearish Forecast for Merus Q3 Earnings - Defense World
US drug body approves Merus' therapy for lung, pancreatic cancer patients - Business Standard
Cramer's Lightning Round: Merus is 'very speculative' - CNBC
Merus Gets FDA Approval for Bizengri Treatment - Marketscreener.com
Merus Announces FDA Approval of BIZENGRI® - GlobeNewswire
Merus Secures FDA Approval for Groundbreaking NRG1+ Cancer Treatment BIZENGRI - StockTitan
Merus’ zenocutuzumab-zbco granted accelerated approval by FDA - TipRanks
Merus price target lowered to $109 from $111 at Guggenheim - Yahoo Finance
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
1.03%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):